Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Intangibles (2021 - 2025)

Gain Therapeutics (GANX) has 5 years of Intangibles data on record, last reported at $114607.0 in Q3 2025.

  • For Q3 2025, Intangibles fell 26.65% year-over-year to $114607.0; the TTM value through Sep 2025 reached $114607.0, down 26.65%, while the annual FY2024 figure was $134268.0, 30.57% down from the prior year.
  • Intangibles reached $114607.0 in Q3 2025 per GANX's latest filing, down from $127857.0 in the prior quarter.
  • Across five years, Intangibles topped out at $213967.0 in Q4 2022 and bottomed at $114607.0 in Q3 2025.
  • Average Intangibles over 5 years is $174342.5, with a median of $189000.0 recorded in 2023.
  • Peak YoY movement for Intangibles: rose 5.61% in 2022, then tumbled 30.57% in 2024.
  • A 5-year view of Intangibles shows it stood at $202609.0 in 2021, then grew by 5.61% to $213967.0 in 2022, then dropped by 9.62% to $193375.0 in 2023, then crashed by 30.57% to $134268.0 in 2024, then fell by 14.64% to $114607.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $114607.0 in Q3 2025, $127857.0 in Q2 2025, and $126291.0 in Q1 2025.